Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 4.8% – Should You Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s stock price fell 4.8% during mid-day trading on Tuesday . The company traded as low as $15.06 and last traded at $14.76. 63,820 shares were traded during mid-day trading, a decline of 95% from the average session volume of 1,262,963 shares. The stock had previously closed at $15.50.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. B. Riley restated a “buy” rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and an average target price of $41.44.

Arrowhead Pharmaceuticals Stock Down 5.4 %

The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The firm has a market cap of $1.91 billion, a P/E ratio of -2.69 and a beta of 0.92. The stock’s fifty day moving average is $18.35 and its two-hundred day moving average is $19.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,850 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the sale, the director now directly owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares of the company’s stock, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 289,167 shares of company stock worth $5,106,735 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $659,000. Charles Schwab Investment Management Inc. grew its position in Arrowhead Pharmaceuticals by 1.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock valued at $19,504,000 after acquiring an additional 12,574 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 941.0% during the third quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock worth $2,368,000 after acquiring an additional 110,516 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $149,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Arrowhead Pharmaceuticals by 40.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 55,188 shares of the biotechnology company’s stock worth $1,069,000 after acquiring an additional 15,784 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.